Literature DB >> 17717121

Effects of buthionine sulfoximine treatment on diaphragm contractility and SR Ca2+ pump function in rats.

A R Tupling1, C Vigna, R J Ford, S C Tsuchiya, D A Graham, S G Denniss, J W E Rush.   

Abstract

The purpose of this study was to examine the effects of glutathione (GSH) depletion and cellular oxidation on rat diaphragm contractility and sarco(endo)plasmic reticulum Ca(2+)-ATPase (SERCA) function in vitro under basal conditions and following fatiguing stimulation. Buthionine sulfoximine (BSO) treatment (n = 10) for 10 days (20 mM in drinking water) reduced (P < 0.05) diaphragm GSH content (nmol/mg protein) and the ratio of GSH to glutathione disulfide (GSH/GSSG) by 91% and 71%, respectively, compared with controls (CTL) (n = 10). Western blotting showed that Hsp70 expression in diaphragm was not increased (P > 0.05) with BSO treatment. As hypothesized, basal peak twitch force (g/mm(2)) was increased (P < 0.05), and fatigability in response to repetitive stimulation (350-ms trains at 100 Hz once every 1 s for 5 min) was also increased (P < 0.05) in BSO compared with CTL. Both Ca(2+) uptake and maximal SERCA activity (mumol.g protein(-1).min(-1)) measured in diaphragm homogenates that were prepared at rest were increased (P < 0.05) with BSO treatment, an effect that could be partly explained by a twofold increase (P < 0.05) in SERCA2a expression with BSO. In response to the 5-min stimulation protocol, both Ca(2+) uptake and maximal SERCA activity were increased (P < 0.05) in CTL but not (P > 0.05) in BSO diaphragm. We conclude that 1) cellular redox state is more optimal for contractile function and fatigability is increased in rat diaphragm following BSO treatment, 2) SERCA2a expression is modulated by redox signaling, and 3) regulation of SERCA function in working diaphragm is altered following BSO treatment.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17717121     DOI: 10.1152/japplphysiol.00529.2007

Source DB:  PubMed          Journal:  J Appl Physiol (1985)        ISSN: 0161-7567


  8 in total

1.  TNF/TNFR1 signaling mediates doxorubicin-induced diaphragm weakness.

Authors:  Laura A A Gilliam; Jennifer S Moylan; Leonardo F Ferreira; Michael B Reid
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2010-11-19       Impact factor: 5.464

2.  Atypical fast SERCA1a protein expression in slow myofibers and differential S-nitrosylation prevented by exercise during long term bed rest.

Authors:  Michele Salanova; Gudrun Schiffl; Dieter Blottner
Journal:  Histochem Cell Biol       Date:  2009-07-31       Impact factor: 4.304

3.  Antimicrobial peptides increase tolerance to oxidant stress in Drosophila melanogaster.

Authors:  Huiwen W Zhao; Dan Zhou; Gabriel G Haddad
Journal:  J Biol Chem       Date:  2010-12-09       Impact factor: 5.157

4.  Heterozygous SOD2 deletion selectively impairs SERCA function in the soleus of female mice.

Authors:  Jessica L Braun; Holt N Messner; Riley E G Cleverdon; Ryan W Baranowski; Sophie I Hamstra; Mia S Geromella; Jeffrey A Stuart; Val A Fajardo
Journal:  Physiol Rep       Date:  2022-05

5.  Doxorubicin acts through tumor necrosis factor receptor subtype 1 to cause dysfunction of murine skeletal muscle.

Authors:  Laura A A Gilliam; Leonardo F Ferreira; Joseph D Bruton; Jennifer S Moylan; Håkan Westerblad; Daret K St Clair; Michael B Reid
Journal:  J Appl Physiol (1985)       Date:  2009-09-24

6.  The effects of buthionine sulfoximine treatment on diaphragm contractility and SERCA pump function in adult and middle aged rats.

Authors:  Ian C Smith; Chris Vigna; Andrew S Levy; Steven G Denniss; James W E Rush; A Russell Tupling
Journal:  Physiol Rep       Date:  2015-09

7.  SERCA2a tyrosine nitration coincides with impairments in maximal SERCA activity in left ventricles from tafazzin-deficient mice.

Authors:  Jessica L Braun; Sophie I Hamstra; Holt N Messner; Val A Fajardo
Journal:  Physiol Rep       Date:  2019-08

Review 8.  Barth syndrome cardiomyopathy: targeting the mitochondria with elamipretide.

Authors:  Hani N Sabbah
Journal:  Heart Fail Rev       Date:  2020-10-01       Impact factor: 4.214

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.